A group of 11 companies banded together in May to launch the Biosimilars Forum to educate and advocate for public policies and practices that encourage access, awareness and adoption of biosimilars. The nonprofit group's founding members are Actavis, Amgen, Boehringer Ingelheim, Coherus BioSciences, the EMD Serono division of Merck KGaA, Hospira, Merck & Co., Pfizer, Samsung Bioepis (a joint venture between Samsung and Biogen), Novartis' Sandoz unit and Teva Pharmaceutical. Some of the founders have been adversaries on a slew of biosimilar-related issues, most recently Amgen and Sandoz (Nat. Biotechnol. 33, 435, 2015). Now with the Forum, the joint focus is on education, access, the regulatory environment, reimbursement and legal affairs relating to biosimilars. The Forum's first offering is an educational handbook, The Next Frontier for Improved Access to Medicines: Biosimilars and Interchangeable Biologic Products.